Invention Grant
US07771748B2 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
失效
5,7,14-三氮杂四环[10.3.1.02,11.04,9] - 十六碳-2（11），3,5,7,9-五烯
![Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene](/docs/US/2010-08-10/US07771748B2/abs.jpg.600x600.jpg)
- Patent Title: Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
- Patent Title (中): 5,7,14-三氮杂四环[10.3.1.02,11.04,9] - 十六碳-2（11），3,5,7,9-五烯
-
Application No.: US10300608Application Date: 2002-11-20
-
Publication No.: US07771748B2Publication Date: 2010-08-10
- Inventor: Mary T. Am Ende , Michael C. Roy , Scott W. Smith , Kenneth C. Waterman , Sara Kristen Moses
- Applicant: Mary T. Am Ende , Michael C. Roy , Scott W. Smith , Kenneth C. Waterman , Sara Kristen Moses
- Applicant Address: US NY New York
- Assignee: Pfizer Inc
- Current Assignee: Pfizer Inc
- Current Assignee Address: US NY New York
- Agent Gregg C. Benson; Garth Butterfield; Mary J. Hosley
- Main IPC: A61K9/30
- IPC: A61K9/30
![Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene](/abs-image/US/2010/08/10/US07771748B2/abs.jpg.150x150.jpg)
Abstract:
The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.
Public/Granted literature
Information query
